全文获取类型
收费全文 | 422470篇 |
免费 | 45689篇 |
国内免费 | 3688篇 |
专业分类
耳鼻咽喉 | 8470篇 |
儿科学 | 13637篇 |
妇产科学 | 8289篇 |
基础医学 | 41388篇 |
口腔科学 | 7507篇 |
临床医学 | 48348篇 |
内科学 | 107889篇 |
皮肤病学 | 14036篇 |
神经病学 | 38795篇 |
特种医学 | 14860篇 |
外国民族医学 | 103篇 |
外科学 | 74976篇 |
综合类 | 3282篇 |
现状与发展 | 73篇 |
一般理论 | 64篇 |
预防医学 | 30258篇 |
眼科学 | 8415篇 |
药学 | 20980篇 |
8篇 | |
中国医学 | 1647篇 |
肿瘤学 | 28822篇 |
出版年
2023年 | 6199篇 |
2022年 | 2972篇 |
2021年 | 7907篇 |
2020年 | 8766篇 |
2019年 | 6997篇 |
2018年 | 15659篇 |
2017年 | 12871篇 |
2016年 | 13950篇 |
2015年 | 14812篇 |
2014年 | 22479篇 |
2013年 | 26474篇 |
2012年 | 23942篇 |
2011年 | 23979篇 |
2010年 | 19638篇 |
2009年 | 21376篇 |
2008年 | 21641篇 |
2007年 | 20926篇 |
2006年 | 22014篇 |
2005年 | 19078篇 |
2004年 | 17380篇 |
2003年 | 14989篇 |
2002年 | 14304篇 |
2001年 | 11236篇 |
2000年 | 10474篇 |
1999年 | 9897篇 |
1998年 | 4963篇 |
1997年 | 4512篇 |
1996年 | 4394篇 |
1995年 | 4090篇 |
1994年 | 2737篇 |
1993年 | 2245篇 |
1992年 | 5201篇 |
1991年 | 4804篇 |
1990年 | 4299篇 |
1989年 | 4196篇 |
1988年 | 3814篇 |
1987年 | 3454篇 |
1986年 | 3351篇 |
1985年 | 2902篇 |
1984年 | 2193篇 |
1983年 | 1910篇 |
1982年 | 1288篇 |
1979年 | 1718篇 |
1978年 | 1298篇 |
1977年 | 1295篇 |
1974年 | 1325篇 |
1973年 | 1345篇 |
1972年 | 1359篇 |
1971年 | 1231篇 |
1970年 | 1206篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
The adrenal cortex gives rise to a biologically heterogenous group of neoplasms, each with a distinct morphology, antigen expression and molecular profile. Adrenal cortical adenomas have excellent prognosis and are usually cured by surgical resection alone, while adrenal cortical carcinomas are very aggressive tumors with a poor prognosis regardless of therapy. These tumors are rare and often challenging for a pathologist to diagnose, as significant overlap exists between benign and malignant lesions in some cases. In this review, we attempt to summarize most important histologic and clinical features of adrenal cortical adenomas and carcinomas, clarify the use of different grading systems, the use of special stains and the differential diagnosis for practicing pathologists. Most relevant hereditary syndromes associated with adrenal cortical tumors are listed. Updates in molecular alterations in adrenal cortical neoplasms and hyperplastic diseases as well as their clinical significance and potential therapeutic implications are also discussed. 相似文献
12.
13.
14.
15.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
16.
17.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
18.
19.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
20.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献